Showing papers by "Rob Knight published in 1998"
TL;DR: Long-term monthly infusions of pamidronate as an adjunct to chemotherapy are superior to chemotherapy alone in reducing skeletal events in stage III multiple myeloma patients, and may improve the survival of patients on salvage therapy.
Abstract: PURPOSETo determine the efficacy and safety of 21 monthly cycles of pamidronate therapy in patients with advanced multiple myeloma.PATIENTS AND METHODSPatients with stage III myeloma and at least one lytic lesion received either placebo or pamidronate 90 mg intravenously administered as a 4-hour infusion monthly for 21 cycles. At study entry, the patients were stratified according to whether they were to receive first-line (stratum 1) or second-line (stratum 2) antimyeloma chemotherapy. Skeletal events (pathologic fracture, radiation or surgery to bone, and spinal cord compression) and hypercalcemia were assessed monthly.RESULTSThe results of the first nine previously reported cycles are extended to 21 cycles. Of the 392 randomized patients, efficacy could be evaluated in 198 who received pamidronate and 179 who received placebo. After 21 cycles, the proportion of patients who developed any skeletal event was lower in the pamidronate-group (P = .015). The mean number of skeletal events per year was less i...
640 citations
TL;DR: Behavioral, physiological and neuroanatomical correlates of the ability to rapidly allocate attention to different regions of visual space are provided.
Abstract: Muller and colleagues provide behavioral, physiological and neuroanatomical correlates of our ability to rapidly allocate attention to different regions of visual space.
4 citations